Matrifen (Fentanyl)

Matrifen (fentanyl) is used in the management of severe pain conditions where continuous opioid therapy is required.

• Severe chronic pain: provides long‑lasting analgesia to improve daily functioning.
• Cancer‑related pain: offers continuous relief for patients with advanced malignancies.
• Breakthrough cancer pain: maintains baseline analgesia while allowing supplemental rescue dosing.

• Fentanyl is a potent μ‑opioid receptor agonist. By binding to μ‑receptors in the central nervous system, it inhibits the release of nociceptive neurotransmitters and reduces neuronal excitability, resulting in analgesia. The transdermal patch delivers fentanyl through the skin into systemic circulation, providing stable plasma levels over several days. Steady drug delivery minimizes peaks and troughs, lowering the risk of withdrawal and improving tolerability.

Fentanyl transdermal therapy may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate feeling of sickness.
• Constipation: reduced bowel movements.
• Dizziness: light‑headed sensation.
• Somnolence: increased sleepiness.
• Skin irritation: redness or itching at the patch site.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure.
• Opioid dependence or withdrawal: signs of addiction or withdrawal upon discontinuation.
• Allergic reaction: rash, swelling, or anaphylaxis.
• Cardiac arrhythmia: irregular heart rhythm.

When prescribing Matrifen, clinicians should observe specific precautions to ensure safe and effective use.

• Patient assessment: evaluate pain severity, opioid tolerance and comorbidities before initiating therapy.
• Dose titration: start with the lowest effective patch strength and adjust gradually under medical supervision.
• Concomitant CNS depressants: avoid or closely monitor use with benzodiazepines, alcohol or other sedatives.
• Respiratory function: monitor breathing in patients with pulmonary disease or sleep apnea.
• Pregnancy and lactation: contraindicated or use only if benefits outweigh risks; consult specialist.
• Store at room temperature: keep patches below 25 °C in original packaging, protect from moisture and direct sunlight.

Fentanyl may interact with other medicines, altering its effects or increasing adverse risks.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise fentanyl levels and cause toxicity.
• MAO inhibitors: increase risk of severe serotonin syndrome.
• CNS depressants (high‑dose benzodiazepines, barbiturates): can cause profound respiratory depression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce fentanyl efficacy.
• Serotonergic agents (SSRIs, SNRIs, tramadol): monitor for serotonin syndrome.
• Diuretics: may enhance hypotensive effects.
• Anticholinergics: may worsen constipation.